The estimated Net Worth of Robert P Lenk is at least 40.1 千$ dollars as of 8 May 2024. Robert Lenk owns over 4,167 units of Plus Therapeutics stock worth over 39,591$ and over the last 17 years he sold PSTV stock worth over 465$. In addition, he makes 0$ as Independent Director at Plus Therapeutics.
Sign up
Robert Lenk PSTV stock SEC Form 4 insiders trading
Robert has made over 8 trades of the Plus Therapeutics stock since 2020, according to the Form 4 filled with the SEC. Most recently he bought 4,167 units of PSTV stock worth 8,501$ on 8 May 2024.
The largest trade he's ever made was buying 9,199 units of Plus Therapeutics stock on 8 November 2023 worth over 14,902$. On average, Robert trades about 3,097 units every 104 days since 2008. As of 8 May 2024 he still owns at least 29,327 units of Plus Therapeutics stock.
You can see the complete history of Robert Lenk stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Robert Lenk biography
Dr. Robert P. Lenk Ph.D. has been appointed as Independent Director of the Company effective 4/1/2020. Dr. Lenk is President of Link Pharmaceuticals, a pharmaceuticals development consultant to multinational corporations and startups. Previously, Dr. Lenk has served as Chief Scientific Officer of MediVector, Inc.; President of the NanoWorks division of Luna Innovations, Inc.; President & CEO of Therapeutics 2000, Inc.; and Vice President of Research & Development at Argus Pharmaceuticals. Dr. Lenk was also a Cofounder of The Liposome Co. and a Staff Fellow of the National Institute of Child Health and Human Development. Dr. Lenk has a PhD and BS from the Massachusetts Institute of Technology.
How old is Robert Lenk?
Robert Lenk is 69, he's been the Independent Director of Plus Therapeutics since 2020. There are 2 older and 11 younger executives at Plus Therapeutics. The oldest executive at Plus Therapeutics, Inc. is Dr. Norman D. LaFrance FACNP, FACP, M.D., 73, who is the Chief Medical Officer & Sr. VP.
What's Robert Lenk's mailing address?
Robert's mailing address filed with the SEC is C/O PLUS THERAPEUTICS INC., 4200 MARATHON BOULEVARD, SUITE 200, AUSTIN, TX, 78756.
Insiders trading at Plus Therapeutics
Over the last 5 years, insiders at Plus Therapeutics have traded over 4,518$ worth of Plus Therapeutics stock and bought 251,584 units worth 410,360$ . The most active insiders traders include Greg Petersen、Marc H Hedrick、Richard J Hawkins. On average, Plus Therapeutics executives and independent directors trade stock every 37 days with the average trade being worth of 8,201$. The most recent stock trade was executed by Marc H Hedrick on 10 September 2024, trading 8,000 units of PSTV stock currently worth 9,840$.
What does Plus Therapeutics do?
Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer and other diseases. Its lead drug candidate is Rhenium-186 NanoLiposome, a patented radiotherapy that targets central nervous system cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. It has a license agreement with NanoTx, Corp. to develop and commercialize NanoTx's glioblastoma treatment. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.
What does Plus Therapeutics's logo look like?
Complete history of Robert Lenk stock trades at Luna Innovations Inc、Plus Therapeutics
Plus Therapeutics executives and stock owners
Plus Therapeutics executives and other stock owners filed with the SEC include:
-
Marc Hedrick,
Chief Executive Officer, Director -
Dr. Marc H. Hedrick M.D.,
Pres, CEO & Director -
Steven Kesten,
President and Chief Medical Officer -
Seijiro Shirahama,
President , Asia Pacific -
Annigje van Es-Johansson,
Independent Director -
Greg Petersen,
Independent Director -
Robert Lenk,
Independent Director -
Howard Clowes,
Independent Director -
Mark Marino,
Chief Medical Officer -
Jeremy Hayden,
Vice President - Business Development, General Counsel -
Desiree Smith,
Principal Accounting Officer, Corporate Controller -
Gregory Stein,
Senior Vice President of Clinical Development -
Andrew Sims,
Chief Financial Officer, Vice President - Finance -
Richard Hawkins,
Chairman of the Board -
Dr. Norman D. LaFrance FACNP, FACP, M.D.,
Chief Medical Officer & Sr. VP -
Desiree Smith,
Corp. Controller, Principal Financial & Accounting Officer -
Gary S. Titus CPA,
Advisor -
Russ Havranek M.B.A., M.S.,
VP of Corp. Strategy, New Product Planning & Investor Relations -
Dr. John K. Fraser,
Chief Scientist -
Andrew J. Sims,
VP of Fin. & CFO -
Es Johansson An Van,
-
Norman D. La France,
Chief Medical Officer